Trial Profile

A Phase I/II Trial of the combination of BRAF and EGFR inhibition in BRAF V600E mutant colorectal, advanced or metastatic lung adenocarcinoma and other cancers

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Vemurafenib (Primary)
Indications Adenocarcinoma; Colorectal cancer; Lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms EVICT
Sponsors Roche

Most Recent Events

13 Jan 2023 Results published in the Clinical Cancer Research
13 Sep 2022 Results (n=25)assessing the utility of ctDNA as a biomarker to predict outcomes and understand mechanisms of treatment resistance in metastatic colorectal from EVICT (erlotinib and vemurafenib in combination trial) presented at the 47th European Society for Medical Oncology Congress
02 Oct 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com